Migraine during pregnancy: options for therapy

Area of Science:

• Neurology
• Obstetrics
• Pharmacology

Background:

• Migraine is a common neurological condition that frequently occurs during pregnancy.
• The first trimester poses the highest risk for fetal development due to potential drug teratogenicity and undiagnosed early pregnancy.

Purpose of the Study:

• To review diagnostic and therapeutic strategies for managing migraine in pregnant individuals.
• To highlight drug safety considerations and treatment challenges during pregnancy.

Main Methods:

• Literature review of existing guidelines and studies on migraine management in pregnancy.
• Analysis of drug safety profiles, focusing on abortifacient and teratogenic potential.
• Discussion of treatment approaches for uncomplicated and chronic migraine, as well as co-morbidities.

Main Results:

• Ergot alkaloids are contraindicated in pregnancy due to teratogenicity.
• Prophylactic agents should be used sparingly, preferably in the second and third trimesters, with propranolol considered relatively safe.
• Paracetamol (acetaminophen) is the first-line treatment for uncomplicated migraine; partial agonist opioids may be considered if paracetamol is insufficient in later trimesters.
• Chronic migraine and co-morbidities present significant therapeutic challenges.

Conclusions:

• Accurate diagnosis and cautious medication selection are crucial for managing migraine in pregnancy.
• Minimizing drug exposure, especially in the first trimester, is paramount.
• Heightened pharmacovigilance is essential for improving the safety and efficacy of migraine treatments in pregnant individuals.